These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25219824)

  • 1. Synergistic in vitro anti-tumor effect of letrozole and everolimus on human endometrial carcinoma Ishikawa cells.
    Lu XY; Yang Y; Xu H; Zeng T; Zhang ZZ
    Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2264-9. PubMed ID: 25219824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study.
    Liu Y; Zhang X; Liu J; Hou G; Zhang S; Zhang J
    Tumour Biol; 2014 Feb; 35(2):1275-86. PubMed ID: 24014089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells.
    Xu C; Li X; Li T; Wang X; Yang Y; Xiao L; Shen H
    Asian Pac J Cancer Prev; 2011; 12(11):2951-7. PubMed ID: 22393970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
    Slomovitz BM; Jiang Y; Yates MS; Soliman PT; Johnston T; Nowakowski M; Levenback C; Zhang Q; Ring K; Munsell MF; Gershenson DM; Lu KH; Coleman RL
    J Clin Oncol; 2015 Mar; 33(8):930-6. PubMed ID: 25624430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro study on blocking mTOR signaling pathway in EGFR-TKI resistance NSCLC.
    Xiang XD; Yu J; Li GF; Xie L; Li H
    Asian Pac J Trop Med; 2014 May; 7(5):394-7. PubMed ID: 25063068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of targeting endometrial stromal sarcoma cells via histone deacetylase and PI3K/AKT/mTOR signaling.
    Quan P; Moinfar F; Kufferath I; Absenger M; Kueznik T; Denk H; Zatloukal K; Haybaeck J
    Anticancer Res; 2014 Jun; 34(6):2883-97. PubMed ID: 24922651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
    Martin LA; Pancholi S; Farmer I; Guest S; Ribas R; Weigel MT; Thornhill AM; Ghazoui Z; A'Hern R; Evans DB; Lane HA; Johnston SR; Dowsett M
    Breast Cancer Res; 2012 Oct; 14(5):R132. PubMed ID: 23075476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
    Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
    Loi S; Michiels S; Baselga J; Bartlett JM; Singhal SK; Sabine VS; Sims AH; Sahmoud T; Dixon JM; Piccart MJ; Sotiriou C
    PLoS One; 2013; 8(1):e53292. PubMed ID: 23301057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-205 inhibits cell growth by targeting AKT-mTOR signaling in progesterone-resistant endometrial cancer Ishikawa cells.
    Zhuo Z; Yu H
    Oncotarget; 2017 Apr; 8(17):28042-28051. PubMed ID: 28427207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic activity of letrozole and sorafenib on breast cancer cells.
    Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
    Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
    Beeram M; Tan QT; Tekmal RR; Russell D; Middleton A; DeGraffenried LA
    Ann Oncol; 2007 Aug; 18(8):1323-8. PubMed ID: 17693645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of signal transduction inhibitors on human endometrial carcinoma cells with differential PTEN gene expression].
    Xiao L; Yang YB; Shen HM; Xu CF; Wang XY; Li XM
    Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):681-5. PubMed ID: 20079181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.
    Yoshioka T; Yogosawa S; Yamada T; Kitawaki J; Sakai T
    Gynecol Oncol; 2013 May; 129(2):425-32. PubMed ID: 23403163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells.
    Li T; Yang Y; Li X; Xu C; Meng L
    Mol Cell Biochem; 2012 Feb; 361(1-2):19-29. PubMed ID: 21952748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells.
    Nishi T; Iwasaki K; Ohashi N; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Kobayashi T; Kodera Y
    Cancer Lett; 2013 May; 331(2):220-9. PubMed ID: 23340172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
    Huang JJ; Li ZM; Huang Y; Huang Y; Tian Y; He XX; Xiao J; Lin TY
    Invest New Drugs; 2012 Feb; 30(1):223-35. PubMed ID: 20960030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aromatase inhibitor letrozole in synergy with curcumin in the inhibition of xenografted endometrial carcinoma growth.
    Liang YJ; Hao Q; Wu YZ; Wang QL; Wang JD; Hu YL
    Int J Gynecol Cancer; 2009 Oct; 19(7):1248-52. PubMed ID: 19823063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.